On the other hand, treatment of BRAF-mutant melanoma patients with BRAF inhibitors in monotherapy or in combination with MEK inhibitors is limited by both acquired and intrinsic drug resistance [11]. The gene discussed is MAP2K7; the disease is melanoma.